Skip to main content
SpringerLink
Log in

Eplerenone

A pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure

  • Adis Pharmacoeconomic Drug Evaluation
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Eplerenone (Inspra™) is a selective aldosterone blocker. When added to standard medical therapy, eplerenone significantly improved morbidity and mortality in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI), in a well designed, placebo-controlled trial known as EPHESUS (Eplerenone Post-acute myocardial infarction Heart failure Efficacy and SUrvival Study). Although eplerenone was generally well tolerated, it was associated with a higher incidence of hyperkalaemia than placebo.

Cost-effectiveness analyses based on this trial have been performed in the US, The Netherlands, Germany, France and Spain. Direct medical costs were analysed based on prospectively collected resource-use data with local costs applied; modelling was conducted to calculate incremental costs per life-year or QALY gained, with survival curves assumed to remain parallel after treatment ended. Eplerenone was associated with a gain of 0.0304 life-years (≈11 days) compared with placebo during the study period.

Based on these analyses, eplerenone was cost effective compared with placebo in patients with LV systolic dysfunction and heart failure after an MI when added to standard therapy for 16 months. The incremental cost per life-year gained for eplerenone versus placebo (for a range of three different life-expectancy projections) was $US10 402–21 876 in the US (year 2001 costs, except for eplerenone [2004]) [equivalent to €12 274–25 814; mid-2001 exchange rate], €5365–12 795 for The Netherlands (year 2003 costs), €6956–14 628 for Germany, €5432–11 423 for France and €8626–18 141 for Spain (year of costing not reported). The US, Dutch, French and Spanish analyses estimated that >90% of observations for incremental cost per life-year gained were below a threshold of $US50 000 or €50 000.

Incremental costs per QALY gained for eplerenone versus placebo in the US, Dutch, French and Spanish analyses were $US15 330–32 405 (€18 089–38 238), €12 148, €8005–16 922 and €12 713–26 873, respectively.

Clinical and pharmacoeconomic data comparing eplerenone with another active drug, such as spironolactone, in this patient population are not available.

In conclusion, when added to standard therapy in patients with LV systolic dysfunction and heart failure after an acute MI, eplerenone was associated with significant reductions in mortality and morbidity compared with placebo. Despite some inherent limitations, available pharmacoeconomic data from Europe and the US indicate that eplerenone is a cost-effective treatment compared with placebo in terms of incremental cost per life-year gained in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Weir R, McMurray JJV. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunc-tion, or both after acute myocardial infarction. Heart 2005; 91 Suppl. II: ii17–20

    Article  PubMed  Google Scholar 

  2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004 Aug 4; 44 (3): 671–719

    Article  PubMed  Google Scholar 

  3. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with STsegment elevation: the Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28–66

    PubMed  Google Scholar 

  4. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 Apr 3; 348 (14): 1309–21

    Article  PubMed  CAS  Google Scholar 

  5. Pfizer Inc. Inspra™ (eplerenone) tablets: prescribing information. 2003 Oct [online]. Available from URL: http://www. pfizer.com [Accessed 2005 Aug 9]

  6. Goldman JH, McKenna WJ. The epidemiology of heart failure secondary to coronary artery disease. Coron Artery Dis 1998; 9: 625–8

    PubMed  CAS  Google Scholar 

  7. Spencer FA, Meyer TE, Gore JM, et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation 2002 Jun 4; 105: 2605–10

    Google Scholar 

  8. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic implications of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004 Feb 3; 109: 494–9

    Google Scholar 

  9. McMurray JJV, Petrie MC, Murdoch DR, et al. Clinical epide-miology of heart failure: public and private health burden. Eur Heart J 1998 Dec; 19 Suppl. P: 9–16

    Google Scholar 

  10. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam study. Eur Heart J 1999 Mar; 20: 447–55

    Google Scholar 

  11. Cleland JGF, Torabi A, Khan NK. Epidemiology and manage-ment of heartfailure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart 2005; 91 Suppl. II: ii7–ii13

    Article  PubMed  Google Scholar 

  12. Lacey L, Tabberer M. Economic burden of post-acute myocardial infarction heart failure in the United Kingdom. Eur J Heart Fail 2005 Jun; 7 (4): 677–83

    Article  PubMed  CAS  Google Scholar 

  13. Hasdai D, Topol EJ, Kilaru R, et al. Frequency, patient charac-teristics, and outcomes of mild-to-moderate heart failure com-plicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J 2003; 145: 73–9

    Article  PubMed  Google Scholar 

  14. Emanuelsson H, Karlson BW, Herlitz J. Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure. Eur Heart J 1994; 15: 761–8

    PubMed  CAS  Google Scholar 

  15. American Heart Association. Heart disease and stroke statistics: 2005 update [online]. Available from URL: http://www.americ anheart.org [Accessed 2005 Jun 22]

  16. Velazquez EJ, Francis GS, Armstrong PW, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J 2004; 25: 1911–9

    Article  PubMed  Google Scholar 

  17. Vaur L, Danchin N, Genes N, et al. Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Am Heart J 1999; 137: 49–58

    Article  PubMed  CAS  Google Scholar 

  18. Solomon SD, Zelenkofske S, McMurray JJV, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581–8

    Article  PubMed  CAS  Google Scholar 

  19. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002; 87: 235–41

    Article  PubMed  CAS  Google Scholar 

  20. Blyth FM, Lazarus R, Ross D, et al. Burden and outcomes of hospitalisation for congestive heart failure. Med J Aust 1997; 167: 67–70

    PubMed  CAS  Google Scholar 

  21. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46 (3): 425–31

    Article  PubMed  CAS  Google Scholar 

  22. Gheorghiade M, Krum H, Chu T-C, et al. Concurrent treatment with eplerenone and standard HF therapy reduces the duration of heart failure hospitalization in patients with post acute myocardial infarction heart failure [abstract no. 2433]. Circulation 2004 Oct 26; 110 (17 Suppl.): 519

    Google Scholar 

  23. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effective-ness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunc tion and heart failure. Circulation 2005 Mar 8; 111 (9): 110613

    Article  Google Scholar 

  24. van Genugten MLL, Weintraub WS, Zhang Z, et al. Cost effectiveness of eplerenone plus standard treatment compared to standard treatment in patients with myocardial infarction complicated by left ventricular systolic dysfunction and heart failure in The Netherlands. Neth Heart J. In press

  25. Kvasz M, Zhang Z, Lenz C, et al. Cost-effectiveness evaluation of eplerenone in patients with heart failure following AMI in Germany [abstract no. PCV 13]. Value Health 2005 May-Jun; 8 (3): 264

    Article  Google Scholar 

  26. Weintraub WS, Zhang Z, Kvasz M, et al. Cost-effectiveness of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction: results from EPHESUS [abstract no. P-2299 plus poster]. Annual Congress of the European Society of Cardiology; 2005 Sep 3-7; Stockholm [online]. Available from URL: http://www.cie.esear dio.org [Accessed 2005 Sep 6]

  27. Zhang Z, Spertus JA, Pitt B, et al. Cost-effectiveness of eplerenone by age and sex subgroups in patients with heart failure after acute myocardial infarction: results from EPHESUS [abstract no. 1753]. Circulation 2004 Oct 26; 110 (17 Suppl.): 367

    Google Scholar 

  28. Peeters A, Mamun AA, Willekens F, et al. A cardiovascular life history: a life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458–66

    Article  PubMed  CAS  Google Scholar 

  29. Saskatchewan Health Research Services. Health services databases: information document. 2005 Sep [online]. Availa-ble from URL: http://www.health.gov.sk.ea [Accessed 2005 Sep 6]

  30. Goldberg RJ, Yarzebski J, Lessard D, et al. A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarc tion: a community-wide perspective. J Am Coll Cardiol 1999; 33 (6): 1533–9

    Article  Google Scholar 

  31. Spencer FA, Meyer TE, Goldberg RJ, et al. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocar dial infarction: a community-wide perspective. J Am Coll Cardiol 1999; 34 (5): 1378–87

    Article  PubMed  CAS  Google Scholar 

  32. FXConverter™. Classic 164 currency converter [online]. Available from URL: http://www.oanda.com/convert/classic [Accessed 2005 Sep 6]

  33. Sacristán JA, Bolaños E, Hernández JM, et al. Publication bias in health economic studies. Pharmacoeconomics 1997 Mar; 11 (3): 289–90

    Article  PubMed  Google Scholar 

  34. Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999; 282 (15): 1453–7

    Article  PubMed  CAS  Google Scholar 

  35. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001 Dec 11; 104 (24): 2996–3007

    Article  PubMed  CAS  Google Scholar 

  36. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005 Jun; 26 (11): 1115–40

    Article  PubMed  Google Scholar 

  37. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999 Sep 2; 341 (10): 709–17

    Article  PubMed  CAS  Google Scholar 

  38. McMurray JJV, O’Meara E. Treatment of heart failure with spironolactone: trial and tribulations. N Engl J Med 2004; 351 (6: 526–8

    Article  PubMed  CAS  Google Scholar 

  39. Tang WHW, Francis GS. Spironolactone in chronic heart failure: all’s well that ends well. J Am Coll Cardiol 2003; 41 (2): 215–6

    Article  PubMed  Google Scholar 

  40. Jönsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5–10

    Article  PubMed  Google Scholar 

  41. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146 (4): 473–81

    CAS  Google Scholar 

  42. Goldman L, Garber AM, Grover SA, et al. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996; 27 (5): 1020–30

    Article  PubMed  CAS  Google Scholar 

  43. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995 Oct; 26 (4): 914–9

    Article  PubMed  CAS  Google Scholar 

  44. Goldman L, Sia ST, Cook EF, et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988; 319 (3): 152–7

    Article  PubMed  CAS  Google Scholar 

  45. Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased R-blocker use following myocardial infarction. JAMA 2000 Dec 6; 284 (21): 2748–54

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Katherine F. Croom & Greg L. Plosker

Authors
  1. Katherine F. Croom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine F. Croom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croom, K.F., Plosker, G.L. Eplerenone. Pharmacoeconomics 23, 1057–1072 (2005). https://doi.org/10.2165/00019053-200523100-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200523100-00008

Keywords

Search

Navigation